A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors

Trial Profile

A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications CNS cancer; Solid tumours; Thyroid cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Mar 2017 Results of a population pharmacokinetic model of Cabozantinib in pediatric patients with reccurent or refractory solid tumors, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 28 Sep 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2017.
    • 28 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Oct 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top